Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A new review of the available literature has concluded that, despite the fact that “prostate cancer is an ideal target for prevention,” there is in fact “no suitable evidence to recommend using any specific nutritional supplement or diet to prevent prostate cancer” at the present time.
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, 5α-reductase inhibitor, diet, nutrition, Prevention, supplement | 1 Comment »
According to a media release we received yesterday, a new paper in the British Journal of Nutrition suggests that “walnuts may help to prevent prostate cancer risk.”
Filed under: Diagnosis, Prevention, Risk | Tagged: Prevention, risk, walnut | 1 Comment »
According to data just reported in The Lancet, some men with low-volume, low-risk prostate cancer may be able to delay progression of their disease if treated only with the 5α-reductase inhibitor dutasteride (Avodart®).
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: dutasteride, low risk, Prevention, progression | 5 Comments »
Newly reported research from a team at the Centenary Institute in Sydney, Australia, has suggested a very different way in which it may be possible to significantly delay or manage the progression of prostate cancer.
Filed under: Drugs in development, Management, Prevention | Tagged: blockade, leucine, Management, Prevention | 2 Comments »
According to a media release issued by Amgen earlier today, the U.S. Food & Drug Administration (FDA) has approved denosumab (marketed as both Prolia® and Xgeva®) as a treatment to increase bone mass in in men with non-metastatic prostate cancer who are already being treated with androgen deprivation therapy (ADT) and who are at high [...]
Filed under: Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: approval, denosumab, fracture, Prevention | Leave a Comment »
In a newly published paper in the journal Integrative Cancer Therapies, the authors report high use of vitamins and supplements among undiagnosed men with a brother who has previously been diagnosed with prostate cancer.
Filed under: Diagnosis, Prevention, Risk | Tagged: brother, Diagnosis, family, Prevention, risk, supplement, vitamin | 1 Comment »
Clinical guidelines issued by the National Comprehensive Cancer Network recommend that prostate cancer patients being treated with androgen deprivation therapy (ADT) — either alone or in combination with radiation therapy — should be screened for osteoporosis and treatment to prevent deterioration of bone health associated with a decline in bone mineral density.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, DXA, fracture, FRAX, guideline, osteopenia, osteoporesis, Prevention | 4 Comments »
The full text of a new article on the potential of whole ginger extract (WGE) in the prevention and treatment of of prostate cancer has recently been published in the British Journal of Nutrition.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Prevention, Treatment, Uncategorized | Tagged: extract, ginger, Prevention, Treatment, WGE | 3 Comments »
The “New” Prostate Cancer InfoLink is delighted to see Dr. Pazdur and colleagues from the U.S. Food & Drug Administration (FDA) present their reasoning for non-approval of the 5α-reductase inhibitors (5-ARIs) dutasteride and finasteride for prevention of prostate cancer in a new article in the New England Journal of Medicine.
Filed under: Diagnosis, Living with Prostate Cancer, Prevention, Risk | Tagged: 5-ARI, 5α-reductase inhibitor, FDA, Prevention | 11 Comments »
Yesterday the US Food & Drug Administration (FDA) updated its guidance on the use of 5α-reductase inhibitors with specific reference to the risk that use of these products may be able to induce high-grade (and therefore high-risk) prostate cancer in a small subset of men treated with these agents.
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, dutasteride, FDA, finasteride, Prevention, risk | 4 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site